Treatment for glioblastoma (GBM)
This site is intended for US healthcare professionals only.

The NovoTAL System

Optimize treatment with Optune (TTFields) using the FDA‐approved NovoTAL System

The NovoTAL System helps you optimize treatment planning for your patients

  • In electric field simulation studies, it was possible to achieve a substantial increase in Tumor Treating Fields (TTFields) intensity to a specific region of the brain by adapting the configuration of paired arrays1
  • Benefits of performing treatment planning for your Optune patients using the NovoTAL System may include:
    • Direct TTFields intensity to the region of active tumor at your clinical discretion2
    • Better correlation of radiographic findings based on your knowledge of the patient’s treatment history and current clinical status2
    • Adapt your patient’s treatment plan by re-mapping if there are significant changes in tumor imaging over time2

Individualize Optune for every patient

  • Treatment planning is an essential component of therapy with Optune

  • The NovoTAL System is utilized to create individualized treatment maps for all clinical and commercial patients starting Optune

The NovoTAL System is supported by reimbursement, technical and training services

  • Treatment mapping with the NovoTAL System is performed as an in-office procedure

    • Novocure™ Reimbursement Services works directly with you and your staff to assist you throughout the reimbursement process

    • The NovoTAL System is licensed by Novocure to certified physicians, with set-up provided

    • Optune certified physicians are required to complete training and certification in order to use the NovoTAL System

To learn more about the NovoTAL System please email

NovoTAL system transducer array layout
NovoTAL system view form

References:1. Wenger C, Salvador R, Basser PJ, Miranda PC. Improving Tumor Treating Fields treatment efficacy in patients with glioblastoma using personalized array layouts [published online December 14, 2015]. Int J Radiat Oncol Biol Phys . 2015: 2. Chaudhry A, Benson L, Varshaver M, et al. NovoTTF™‐100A System (Tumor Treating Fields) transducer array layout planning for glioblastoma: a NovoTAL™ System user study. World J Surg Oncol. 2015;13:316. doi:10.1186/s1­2­9­5­7­‐­0­1­5­‐­0­7­2­2­‐­3. 3. NovoTAL User Manual QSD‐QR‐700 Revision 1.4. Novocure January 2015.

How Optune works

See how Tumor Treating Fields (TTFields) disrupt mitosis and inhibit tumor growth.

Watch video

Review user study results

Examine clinical outcomes from a NovoTAL™ System user study.

See the Data

Indications For Use

Optune is intended as a treatment for adult patients (22 years of age or older) with histologically-confirmed glioblastoma multiforme (GBM).